Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-026076
Filing Date
2021-04-08
Accepted
2021-04-08 16:35:11
Documents
1
Period of Report
2021-04-06

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 14077
  Complete submission text file 0001209191-21-026076.txt   15556
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421
Business Address
Knowles Julius (Reporting) CIK: 0001808365 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 21815266